	Application No.	Applicant(s)
Notice of Allowability	40/040 504	MARILLIA ET AL
	10/642,531 Examiner	MARILLIA ET AL.
	David H. Kruse	1638
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.		
1. This communication is responsive to the Amendment filed 19 April 2006.		
2. The allowed claim(s) is/are <u>1,3-10,12-15 and 17-25</u> .		
3. ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) ☐ All b) ☐ Some* c) ☐ None of the:		
1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No.		
2. Certified copies of the priority documents have been received in Application No		
3. Copies of the certified copies of the priority documents have been received in this national stage application from the		
International Bureau (PCT Rule 17.2(a)).		
* Certified copies not received:		
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		
4. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.		
5. CORRECTED DRAWINGS (as "replacement sheets") must be submitted.		
(a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached		
1) ☐ hereto or 2) ☐ to Paper No./Mail Date		
(b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date		
Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).		
6. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.		
Attachment(s)		
1. Notice of References Cited (PTO-892)	Notice of Informal P	atent Application (PTO-152)
2. Notice of Draftperson's Patent Drawing Review (PTO-948)	6. ⊠ Interview Summary Paper No./Mail Dat	
3. Information Disclosure Statements (PTO-1449 or PTO/SB/0		
Paper No./Mail Date	8. Examiner's Stateme	ent of Reasons for Allowance
of Biological Material	9. Other	

EXAMINER'S AMENDMENT

1. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Alan Turner on 5 July 2006.

The application has been amended as follows:

At claim 3, line 2, "corn," has been deleted.

Claim 5 (Amended) The transgenic plant of claim 1, wherein the nucleic acid sequence further [includes a gene] <u>comprises a nucleic acid sequence</u> encoding a pyruvate dehydrogenase kinase oriented in an anti-sense direction.

At claim 12, line 2, "corn," has been deleted.

At claim 14, "obtained" has been replaced with -- produced --.

Claim 15 (Amended) A process for modulating mitochondrially generated acetyl-COA and/or respiration rate in a transgenic plant, the process comprising:

cloning a gene encoding a *Brassica* pyruvate dehydrogenase kinase protein into a vector, wherein the gene comprises a sequence selected from the group of sequences consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3 and SEQ ID NO:4; transforming the vector into a plant to produce [the] <u>a</u> transgenic plant; and <u>selecting a transgenic plant having reduced</u> [reducing] production of the *Brassica* pyruvate dehydrogenase kinase protein in the transgenic plant.

Application/Control Number: 10/642,531

Art Unit: 1638

At claim 17, line 2, "corn," has been deleted.

Claim 19 (Amended) The process according to claim 15, wherein the [step for reducing production of] gene encoding the Brassica pyruvate dehydrogenase kinase protein [comprises positioning the gene encoding the Brassica pyruvate dehydrogenase kinase protein] is in an anti-sense orientation in the vector.

At claim 21, line 1, -- isolated -- has been inserted before "DNA".

At claim 22, line 2, "a sequence" has been amended to -- the sequence --.

Claim 23 (New) The transgenic plant of claim 3 wherein the member of the *Gramineae* is selected from the group consisting of corn, wheat, barley, rice, oat, sorghum and rye.

Claim 24 (New) The process of claim 12 wherein the member of the *Gramineae* is selected from the group consisting of corn, wheat, barley, rice, oat, sorghum and rye.

Claim 25 (New) The process of claim 17 wherein the member of the *Gramineae* is selected from the group consisting of corn, wheat, barley, rice, oat, sorghum and rye.

2. Applicants' attorney Alan Turner approved the above amendments to put the application in condition for allowance.

Terminal Disclaimer

3. The terminal disclaimer filed on 11 April 2006 disclaiming the terminal portion of any patent granted on this application, which would extend beyond the expiration date of any patent granted on Application Number 10/222,075 has been reviewed and is accepted. The terminal disclaimer has been recorded.

Application/Control Number: 10/642,531 Page 4

Art Unit: 1638

4. Any inquiry concerning this communication or earlier communications from the examiner should be directed to David H. Kruse, Ph.D. whose telephone number is (571) 272-0799. The examiner can normally be reached on Monday to Friday from 8:00 a.m. to 4:30 p.m.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Anne Marie Grunberg can be reached at (571) 272-0975. The central FAX number for official correspondence is 571-273-8300.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group Receptionist whose telephone number is (571) 272-1600.

DAVID H. KRUSE, PH.D.
PRIMARY EXAMINER

Down Marse

David H. Kruse, Ph.D. 5 July 2006

5. Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to (571) 272-0547.

Patent applicants with problems or questions regarding electronic images that can be viewed in the Patent Application Information Retrieval system (PAIR) can now contact the USPTO's Patent Electronic Business Center (Patent EBC) for assistance. Representatives are available to answer your questions daily from 6 am to midnight (EST). The toll free number is (866) 217-9197. When calling please have your application serial or patent number, the type of document you are having an image problem with, the number of pages and the specific nature of the problem. The Patent Electronic Business Center will notify applicants of the resolution of the problem within 5-7 business days. Applicants can also check PAIR to confirm that the problem has been corrected. The USPTO's Patent Electronic Business Center is a complete service center supporting all patent business on the Internet. The USPTO's PAIR system provides Internet-based access to patent application status and history information. It also enables applicants to view the scanned images of their own application file folder(s) as well as general patent information available to the public.

For all other customer support, please call the USPTO Call Center (UCC) at 800-786-9199.